GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Escitalopram tablets (adults)

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug2 sources available - open source summaries, references and comparisons

Lexapro

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

Escitalopram tablets (adults) - selected U.S. labeling

Product / population
Adult major depressive disorder and generalized anxiety disorder; oral escitalopram tablets. Pediatric and oral-solution dosing are outside this summary.
Renal measure
CrCl in mL/min for the below-20 data boundary; no severe-renal dose algorithm.
Labeled basic dosing

The adult starting/recommended dose is 10 mg orally once daily. Based on response and tolerability, increase no sooner than one week to a maximum 20 mg/day. Most older adults and patients with hepatic impairment use 10 mg/day.

Renal information and dialysis

No change is needed for mild or moderate renal impairment. At adult CrCl below 20 mL/min, a recommended dosage has not been determined. A dialysis-specific regimen is not supplied.

Selected warnings and limits

Monitor clinical worsening or suicidality, serotonin syndrome and hyponatremia; screen for bipolar disorder and review interacting medicines.

Source revision: Label revision date not separately recorded; retrieval date is not the revision date. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9c68f89b-1d34-4735-9631-817f012935d7

Scope: Selected dosing/renal sections read; concise local summary, not full prescribing information. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Official product label

Escitalopram tablets (adults) - selected U.S. labeling

Adult major depressive disorder and generalized anxiety disorder; oral escitalopram tablets. Pediatric and oral-solution dosing are outside this summary.

Renal method: CrCl in mL/min for the below-20 data boundary; no severe-renal dose algorithm.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Handbook

Renal Drug Handbook, fifth edition - Escitalopram tablets (adults)

Historical renal/RRT cross-check for the named ingredient; not a current U.S. prescribing instruction.

Renal method: Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods.
Retrieved: 2026-09-05

Read local renal result

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Official source

Escitalopram tablets (adults) - selected U.S. labeling

Adult major depressive disorder and generalized anxiety disorder; oral escitalopram tablets. Pediatric and oral-solution dosing are outside this summary.

Method: CrCl in mL/min for the below-20 data boundary; no severe-renal dose algorithm.

Renal information and dialysisRead this complete source summary
Handbook source

Renal Drug Handbook, fifth edition - Escitalopram tablets (adults)

Historical renal/RRT cross-check for the named ingredient; not a current U.S. prescribing instruction.

Method: Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods.

Historical renal and dialysis observationsRead this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeEscitalopram tablets (adults) - selected U.S. labelingRenal Drug Handbook, fifth edition - Escitalopram tablets (adults)
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9c68f89b-1d34-4735-9631-817f012935d7

Product and population scope

Adult major depressive disorder and generalized anxiety disorder; oral escitalopram tablets. Pediatric and oral-solution dosing are outside this summary.

RDM31-escitalopram-tablets-scope · Source section: Editorial scope tied to selected U.S. labelRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Escitalopram tablets (adults) - selected U.S. labeling

Open original reference

Open / share this exact local source

U.S. product labeling / DailyMed · Adult major depressive disorder and generalized anxiety disorder; oral escitalopram tablets. Pediatric and oral-solution dosing are outside this summary.

Renal method: CrCl in mL/min for the below-20 data boundary; no severe-renal dose algorithm.
Source date: Label revision date not separately recorded; retrieval date is not the revision date.
Retrieved: 2026-09-05

Selected dosing/renal sections read; concise local summary, not full prescribing information.

Labeled basic dosing

The adult starting/recommended dose is 10 mg orally once daily. Based on response and tolerability, increase no sooner than one week to a maximum 20 mg/day. Most older adults and patients with hepatic impairment use 10 mg/day.

RDM31-escitalopram-tablets-label-dose · Source locator: 2.1, 2.2, 2.5

Renal information and dialysis

No change is needed for mild or moderate renal impairment. At adult CrCl below 20 mL/min, a recommended dosage has not been determined. A dialysis-specific regimen is not supplied.

RDM31-escitalopram-tablets-label-renal · Source locator: 2.5; 8.7

Selected warnings and limits

Monitor clinical worsening or suicidality, serotonin syndrome and hyponatremia; screen for bipolar disorder and review interacting medicines.

RDM31-escitalopram-tablets-label-limits · Source locator: Boxed warning; 2.4; 5

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9c68f89b-1d34-4735-9631-817f012935d7
Retrieved
2026-09-05
DailyMed Set ID
9c68f89b-1d34-4735-9631-817f012935d7
Renal-function method
CrCl in mL/min for the below-20 data boundary; no severe-renal dose algorithm.
Source date/version
Label revision date not separately recorded; retrieval date is not the revision date.
Hash meaning
SHA-256 identifies this local summary, not original SPL XML or label PDF.
Local summary SHA-256
7d6ce892c9086cdb4520017d8fae78115c6c5e5276152162e6a4c6913ec0ebf9
Separate handbook layer

Renal Drug Handbook cross-check

Handbook

Renal Drug Handbook, fifth edition - Escitalopram tablets (adults)

Open / share this exact local source

UK Renal Pharmacy Group / CRC Press · Historical renal/RRT cross-check for the named ingredient; not a current U.S. prescribing instruction.

Renal method: Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods.
Source date: Fifth edition, 2019
Retrieved: 2026-09-05

Historical source, separately displayed. Renal tables were read with page-image inspection.

Historical renal and dialysis observations

The book retains usual dosing at 30-50 mL/min; at 10-30 and below 10, it favors low initiation and slow titration. HD/high-flux removal is described as absent, and peritoneal/continuous removal as unlikely.

RDM31-escitalopram-tablets-book · Source locator: Dose in renal impairment; renal replacement therapies; Other information

Source-specific limits

This is historical cautious-use advice where the label does not establish a dose below CrCl 20. The printed book bands overlap at 30; they are not an automated algorithm.

Source identity and provenance
Retrieved
2026-09-05
Handbook page
Printed page(s) 386-387; PDF page(s) 405,406
Renal-function method
Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods.
Source date/version
Fifth edition, 2019
U.S. product identity basis
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9c68f89b-1d34-4735-9631-817f012935d7
Hash meaning
SHA-256 identifies the local paraphrase; the source PDF is not redistributed.
Local summary SHA-256
eb79c1e11a7a59948bbcf943c8983e325e7e56a69daecf749b605684bf6cf7df

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 0 RX List, 0 professional, 1 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9c68f89b-1d34-4735-9631-817f012935d7
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
11c82519c49aba357768684539899c3ca1d0b8835559225b335bf5cc53c3cb37
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report